A phase I study of YHI-1001

A phase I study of YHI-1001 in patients with solid tumors

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221834

Enrollment

Registered

2012-06-21

Start date

2012-06-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor

Interventions

investigational material(s) Generic name etc : YHI-1001 INN of investigational material : Resminostat Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with histologically and cytologically confirmed solid tumors (2)Patients who have completed conventional therapies for their tumors or patients with tumors for which no conventional therapy exists (3)ECOG performance status (PS) :0-1 (4) Patients who are able to take YHI-1001 orally and do not have GI dysfunction judged to have impact on abosorption of YHI-1001

Exclusion criteria

Exclusion criteria: (1)Patients who have taken HDAC inhibitors (2)Patients with significant cardiovascular disease (3)Patients with symptomatic brain metastatis requiring treatment

Design outcomes

Primary

Measure	Time frame
safety CTCAE v4.0	—

Secondary

Measure	Time frame
efficacy, pharmacokinetics and pharmacodynamics profile RECIST ver1.1	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026